- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Early Palliative Care Improves Quality of Life in NSCLC
Journal of Clinical Oncology
Early palliative care for patients with terminal non-small-cell lung cancer (NSCLC) improves the timing of final chemotherapy administration and is associated with an earlier transition to hospice care, according to a study published online Dec. 27 in the .
Joseph A. Greer, M.D., of the Massachusetts General Hospital Cancer Center in Boston, and colleagues investigated whether early palliative care affected the frequency and timing of chemotherapy use and hospice care for patients with metastatic NSCLC. This 18-month study involved 151 tertiary care patients with newly diagnosed metastatic NSCLC who were randomized to receive either early palliative care integrated with standard oncology care or standard oncology care alone.
Measures of outcome included the number and types of chemotherapy regimens, and the frequency and timing of chemotherapy administration and hospice referral.
Read the full story at: http://www.physiciansbriefing.com/Article.asp?AID=660207
Source: HealthDay
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Powles Highlights “Transformative” Benefit of EV Plus Pembro While Sharing Long-Term Data for EV-302
February 15th 2025The lead investigator for EV-302 said not long ago, survival of 12 to 14 months in this type of bladder cancer was considered an achievement; in this study, median overall survival was 34 months after treatment with enfortumab vedotin (EV) and pembrolizumab (pembro).
Read More
Analysis Looks at Benefits, Toxicity of ADC Combinations in Advanced Bladder Cancer
February 15th 2025City of Hope's Salvador Jaime-Casas, MD, discusses a systematic review of recent trials examining objective response rate and adverse events of antibody-drug conjugate (ADC) combinations in advanced urothelial cancer.
Read More
